1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 Mar 2020
Admin
News Article

Wuxi Biologics And Bayer Enter Into Acquisition Agreement

Wuxi Biologics, A Leading Global Open-Access Biologics Technology Platform Company Offering End-To-End Solutions For Biologics Discovery, Development And Manufacturing, And Bayer Jointly Announced An Acquisition Agreement That Wuxi Biologics Germany Gmbh Will Take Over The Operations Of One Of Bayer'S Final Drug Product Manufacturing Plants In Leverkusen, Germany, And Purchase The Associated Equipment, In Combination With A Long-Term Lease Contract For The Building.Based On A Manufacturing Agreement To Be Negotiated, The Plant Would Be Operated By Wuxi Biologics And Serve As A Back-Up Site For The Final Product Manufacturing Of Kovaltry&Trade;, An Antihemophilic Factor (Recombinant). The Transaction Is Expected To Be Concluded In The Coming Months Subject To The Satisfaction Of Customary Closing Conditions. Financial Details Were Not Disclosed."We Are Excited To Sign This Acquisition Agreement With Bayer, Allowing Us To Have Quick Access To High Quality Drug Product Manufacturing Capacities And Capabilities," Said Dr. Chris Chen, Ceo Of Wuxi Biologics. "Our Business In Eu, Us And China Market Has Experienced Robust Growth In The Past Few Years. This Additional Drug Product Plant Further Confirms Our Commitment To 'Global Dual Sourcing Within Wuxi Biologics' Strategy. Wuxi Biologics Will Continue To Expand Our Worldwide Capacity, Providing Global Partners With A Robust And Premier-Quality Supply Chain Network To Benefit Patients Worldwide

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!